Roche Holding AG EBIT

The latest EBIT for RHHBY is $30B as of June 2026. That compares with $29B in the prior-year period — up 0.4% year over year. That is above the Healthcare sector average of $23B. Investors often review this figure alongside Roche Holding AG's historical trend and sector peers before judging valuation or financial health.

Over the past year, RHHBY's EBIT moved from $29B to $30B — a 0.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Roche Holding AG's operating scale or balance-sheet position.

Against Healthcare companies, RHHBY currently prints $30B for EBIT, while the sector average sits near $23B. That is roughly 30.0% above the sector mean. Large gaps often invite a closer look at Roche Holding AG's growth, margins, and balance sheet.

A EBIT figure of $30B for RHHBY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting RHHBY's EBIT ($30B), review year-over-year change from $29B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.